Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2018 - 2019)

Zevra Therapeutics (ZVRA) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $60.4 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Long-Term Deferred Tax changed N/A year-over-year to $60.4 million, compared with a TTM value of $60.4 million through Dec 2018, changed N/A, and an annual FY2018 reading of $60.4 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $60.4 million for Q4 2018 at Zevra Therapeutics, up from $18.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $60.4 million in Q4 2018 and bottomed at $18.3 million in Q4 2014.